Pharvaris Netherlands B.V.

Quick facts

Phase 2 pipeline

• Deucrictibant high dose · Cardiovascular
  Deucrictibant is a bradykinin receptor 2 antagonist.
• Deucrictibant low dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Pharvaris Netherlands B.V. portfolio CI brief
• Pharvaris Netherlands B.V. pipeline updates RSS